4.6 Article

Use of aspirin combinations with caffeine and increasing headache frequency: a prospective population-based study

Journal

PAIN
Volume 156, Issue 9, Pages 1747-1754

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/j.pain.0000000000000239

Keywords

Combination analgesics; Population-based; Epidemiology; Chronic headache; Aspirin

Funding

  1. German Ministry for Education and Research, BMBF
  2. Bayer Vital GmbH, Leverkusen, Germany
  3. Addex Pharma
  4. Alder
  5. Allergan
  6. Almirall
  7. Amgen
  8. AstraZeneca
  9. Autonomic Technology
  10. Bayer Vital
  11. Berlin Chemie
  12. Bohringer Ingelheim
  13. Bristol-Myers Squibb
  14. Chordate
  15. CoLucid
  16. Coherex
  17. Electrocore
  18. GlaxoSmithKline
  19. Grunenthal
  20. Janssen-Cilag
  21. Labrys Biologicals
  22. Lilly
  23. La Roche
  24. 3M Medica
  25. Menerini
  26. Minster
  27. MSD
  28. Novartis
  29. Johnson Johnson
  30. Pierre Fabre
  31. Pfizer
  32. Schaper und Brummer
  33. Sanofi
  34. St Jude Medical
  35. Weber Weber
  36. Bayer
  37. GSK
  38. German Research Council Assessment (DFG)
  39. Federal Ministry of Education and Research (BMBF)
  40. European Union (EU)
  41. Allergan, Inc.

Ask authors/readers for more resources

Combinations of analgesics with caffeine have been discussed as bearing a risk for headache chronicity. We investigated whether aspirin with caffeine (ASA+) increases headache frequency compared with aspirin alone in migraine, tension-type headache (TTH), and migraine + TTH (MigTTH). The population-based German Headache Consortium Study, which included participants aged 18 to 65 years, collected information about headache and analgesics at baseline (2003-2007, t(0), response rate: 55.2%), first follow-up after 1.87 +/- 0.39 years (t(1), 37.2%), and second follow-up after 3.26 +/- 0.60 years (t(2), 38.8%). We included participants with headache at t(0), aspirin intake, ASA+ or no analgesics at t(0) and t(2), and known headache frequency. Linear regression was used to estimate changes of headache frequency (Delta t(2)-t(0)) and 95% confidence intervals depending on analgesic intake, stratified by headache subtypes, adjusting for sex, age, analgesics at t(1), changes of headache frequency at t(1), drinking, smoking, body mass index, education, headache frequency at t(0). Of 509 participants (56.0% women, 42.0 +/- 11.8 years [mean +/- SD]), 45.2% reported aspirin intake (41.3 +/- 10.9 years, 59.6% women, headache days at t(0): 2.8 +/- 3.1 d/mo, t(2): 3.6 +/- 4.1 d/mo), 11.8% ASA+ intake (46.0 +/- 9.8 years, 73.3%, t(0): 4.8 +/- 6.1 d/mo, t(2): 5.3 +/- 5.1 d/mo), and 43.0% no analgesics (41.6 +/- 13.1 years, 47.5%, t(0): 3.8 +/- 6.2 d/mo, t(2): 5.3 +/- 6.6 d/mo). There was no increase in headache frequency in participants with ASA+ intake compared with aspirin (adjusted, all headache: -0.34 d/mo [95% confidence intervals: -2.50 to 1.82], migraine: -1.36 d/mo [-4.76 to 2.03], TTH: -0.57 d/mo [-4.97 to 3.84], MigTTH: 2.46 d/mo [-5.19 to 10.10]) or no analgesics (all headache: -2.24 d/mo [-4.54 to 0.07], migraine: -3.77 d/mo [-9.22 to 1.68], TTH: -4.68 d/mo [-9.62 to 0.27]; MigTTH: -3.22 d/mo [-10.16 to 3.71]). In our study, ASA+ intake did not increase headache frequency compared with aspirin or no analgesics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available